These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16627255)

  • 1. The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: results of a prospective trial.
    Lee S; Kim YJ; Eom KS; Min CK; Kim HJ; Cho SG; Lee JW; Min WS; Kim CC
    Haematologica; 2006 May; 91(5):671-4. PubMed ID: 16627255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
    Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R
    Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of acute promyelocytic leukemia: a single institution experience.
    Ruiz-Argüelles GJ; Morales-Toquero A; Gómez-Rangel JD; López-Martínez B; Ruiz-Delgado GJ; Reyes-Núñez V
    Rev Invest Clin; 2005; 57(3):415-9. PubMed ID: 16187701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy.
    Breccia M; Diverio D; Noguera NI; Visani G; Santoro A; Locatelli F; Damiani D; Marmont F; Vignetti M; Petti MC; Lo Coco F
    Haematologica; 2004 Jan; 89(1):29-33. PubMed ID: 14754603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monitoring of minimal residual disease in patients with acute promyelocytic leukemia].
    Shuravina EN; Parovichnikova EN; Demidova IA; Misiurin AV; Isaev VG; Ol'shanskaia IuV; Savchenko VG
    Ter Arkh; 2006; 78(7):25-31. PubMed ID: 16944747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detecting PML-RARalpha transcript in acute promyelocytic leukemia using real-time quantitative RT-PCR.
    Zhu HH; Liu YR; Qin YZ; Jiang B; Shan FX; Wu SL; Yang PD; Zhao J; Lu DP
    Chin Med J (Engl); 2007 Oct; 120(20):1803-8. PubMed ID: 18028775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group.
    Ortega JJ; Madero L; Martín G; Verdeguer A; García P; Parody R; Fuster J; Molines A; Novo A; Debén G; Rodríguez A; Conde E; de la Serna J; Allegue MJ; Capote FJ; González JD; Bolufer P; González M; Sanz MA;
    J Clin Oncol; 2005 Oct; 23(30):7632-40. PubMed ID: 16234524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.
    Santamaría C; Chillón MC; Fernández C; Martín-Jiménez P; Balanzategui A; García Sanz R; San Miguel JF; González MG
    Haematologica; 2007 Mar; 92(3):315-22. PubMed ID: 17339180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. All-transretinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia.
    Al Bahar S; Pandita R; Bavishi K; Kreze O
    Indian J Cancer; 2004; 41(3):125-8. PubMed ID: 15472411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
    Xin L; Wan-jun S; Zeng-jun L; Yao-zhong Z; Yun-tao L; Yan L; Chang-chun W; Qiao-chuan L; Ren-chi Y; Ming-zhe H; Jian-xiang W; Lu-gui Q
    Leuk Res; 2007 Jun; 31(6):765-71. PubMed ID: 17007927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
    Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of autologous bone marrow transplantation as consolidation therapy in acute promyelocytic leukemia patients in complete remission.
    Ottaviani E; Martinelli G; Testoni N; Visani G; Tani M; Tura S
    Haematologica; 1998 Nov; 83(11):1051-5. PubMed ID: 9864933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.
    Diverio D; Rossi V; Avvisati G; De Santis S; Pistilli A; Pane F; Saglio G; Martinelli G; Petti MC; Santoro A; Pelicci PG; Mandelli F; Biondi A; Lo Coco F
    Blood; 1998 Aug; 92(3):784-9. PubMed ID: 9680345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia].
    Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
    Grimwade D; Jovanovic JV; Hills RK
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):53-61. PubMed ID: 24907017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematological and molecular remission with combination chemotherapy in a patient with PLZF-RARalpha acute promyelocytic leukemia (APML).
    George B; Poonkuzhali B; Srivastava VM; Chandy M; Srivastava A
    Ann Hematol; 2005 Jun; 84(6):406-8. PubMed ID: 15592671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
    Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of peripheral blood progenitor cells demonstrates limitations of minimal residual disease diagnosis in a case of acute promyelocytic leukemia.
    Karlic HI; Mühlberger H; Pavlova BG; Pfeilstöcker M; Salamon J; Pittermann E; Heinz R; Koller E
    Bone Marrow Transplant; 1995 Jun; 15(6):999-1000. PubMed ID: 7581106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favourable outcome in an APL patient with PLZF/RARalpha fusion gene: quantitative real-time RT-PCR confirms molecular response.
    Cassinat B; Guillemot I; Moluçon-Chabrot C; Zassadowski F; Fenaux P; Tournilhac O; Chomienne C
    Haematologica; 2006 Dec; 91(12 Suppl):ECR58. PubMed ID: 17194664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
    Maurillo L; Buccisano F; Del Principe MI; Del Poeta G; Spagnoli A; Panetta P; Ammatuna E; Neri B; Ottaviani L; Sarlo C; Venditti D; Quaresima M; Cerretti R; Rizzo M; de Fabritiis P; Lo Coco F; Arcese W; Amadori S; Venditti A
    J Clin Oncol; 2008 Oct; 26(30):4944-51. PubMed ID: 18606980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.